Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Historic Non-Current Deffered Revenue for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2022 value amounting to $6.6 million.

  • Xeris Biopharma Holdings' Non-Current Deffered Revenue fell 265.16% to $6.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $6.6 million, marking a year-over-year decrease of 265.16%. This contributed to the annual value of $6.9 million for FY2021, which is 383.16% up from last year.
  • According to the latest figures from Q3 2022, Xeris Biopharma Holdings' Non-Current Deffered Revenue is $6.6 million, which was down 265.16% from $6.8 million recorded in Q2 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Non-Current Deffered Revenue peaked at $6.9 million during Q1 2022, and registered a low of $6.6 million during Q4 2020.
  • For the 3-year period, Xeris Biopharma Holdings' Non-Current Deffered Revenue averaged around $6.8 million, with its median value being $6.8 million (2021).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 383.16% in 2021, then plummeted by 265.16% in 2022.
  • Quarter analysis of 3 years shows Xeris Biopharma Holdings' Non-Current Deffered Revenue stood at $6.6 million in 2020, then rose by 3.83% to $6.9 million in 2021, then dropped by 3.46% to $6.6 million in 2022.
  • Its Non-Current Deffered Revenue stands at $6.6 million for Q3 2022, versus $6.8 million for Q2 2022 and $6.9 million for Q1 2022.